

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited taken responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



泰 達

天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code : 8189)

RESIGNATION OF JOINT CHIEF EXECUTIVE OFFICER

RESIGNATION OF JOINT CHIEF EXECUTIVE OFFICER

Mr. Qin Wenhua ("Mr. Qin") resigned as the Joint CEO due to his busy schedule and his other business engagements with effect from 26 March 2024.

Mr. Wang has confirmed that, he does not have any disagreement with the Board and that there is no other matter that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its appreciation to Mr. Qin for his valuable contributions to the Company during his tenure of office of the Company.

DEVIATION FROM THE CORPORATE GOVERNANCE CODE

Before Mr. Qin resigned as the Joint CEO, he and Ms. Sun Li ("Ms. Sun") jointly served as the Joint CEO. After Mr. Qin resigned as the joint CEO, Ms. Sun became the CEO of the Company.

As Ms. Sun now serves as both the Chairman and the CEO, such practice deviates from code provision A.2.1 of the Code of Corporate Governance (the "Code"). The Board is of the opinion that it is appropriate and in the best interests of the Company for Ms. Sun to hold both positions as it helps to maintain the continuity of the policies and the stability of the operations of the Company. The Company has been proactively recruiting candidates for the post of CEO through different means so as to fulfill the requirements of A.2.1 of the Code as soon as possible for increasing the transparency and independence of corporate governance. Save as disclosed above, there is no information in relation to the appointment of Ms. Sun as the CEO which is required to be disclosed pursuant to Rule 17.50(2) of GEM Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
26 March 2024

As at the date of this announcement, the executive directors of the Company are Sun Li and He Xin; the non-executive directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.